About KalVista Pharmaceuticals (NASDAQ:KALV)
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products under development include KVD818, an orally delivered molecule that is in Phase I clinical trial for the treatment of HAE; KVD001, an intravitreally administered plasma kallikrein inhibitor that has completed a Phase I clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein that is in preclinical safety studies for use against human proteases related to plasma kallikrein. The company is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KALV
CUSIPN/A
Phone857-999-0075
Debt
Debt-to-Equity RatioN/A
Current Ratio2.73%
Quick Ratio2.73%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$1.50 million
Price / Sales66.38
Cash FlowN/A
Price / CashN/A
Book Value$3.22 per share
Price / Book2.86
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-18,600,000.00
Net Margins-527.53%
Return on Equity-65.77%
Return on Assets-46.48%
Miscellaneous
Employees28
Outstanding Shares10,800,000
KalVista Pharmaceuticals (NASDAQ:KALV) Frequently Asked Questions
What is KalVista Pharmaceuticals' stock symbol?
KalVista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."
How were KalVista Pharmaceuticals' earnings last quarter?
KalVista Pharmaceuticals (NASDAQ:KALV) announced its earnings results on Friday, March, 16th. The specialty pharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter. The specialty pharmaceutical company had revenue of $2.33 million for the quarter. KalVista Pharmaceuticals had a negative return on equity of 65.77% and a negative net margin of 527.53%. View KalVista Pharmaceuticals' Earnings History.
What price target have analysts set for KALV?
1 Wall Street analysts have issued 1-year price objectives for KalVista Pharmaceuticals' stock. Their forecasts range from $27.00 to $27.00. On average, they anticipate KalVista Pharmaceuticals' stock price to reach $27.00 in the next twelve months. View Analyst Ratings for KalVista Pharmaceuticals.
Who are some of KalVista Pharmaceuticals' key competitors?
Some companies that are related to KalVista Pharmaceuticals include Scpharmaceuticals (SCPH), Marinus Pharmaceuticals (MRNS), Ra Pharmaceuticals (RARX), POXEL (PXXLF), Xoma (XOMA), Summit Therapeutics (SMMT), Nabriva Therapeutics (NBRV), Zafgen (ZFGN), Teligent (TLGT), Protagonist Therapeutics (PTGX), Spero Therapeutics (SPRO), Kamada (KMDA), Immune Design (IMDZ), Spring Bank Pharmaceuticals (SBPH), Proteostasis Therapeutics (PTI), Avid Bioservices (CDMO), Intec Pharma (NTEC) and XBiotech (XBIT).
Who are KalVista Pharmaceuticals' key executives?
KalVista Pharmaceuticals' management team includes the folowing people:
- Mr. Thomas Andrew Crockett M.B.A., CEO & Director (Age 43)
- Mr. Benjamin L. Palleiko, Chief Financial Officer (Age 52)
- Mr. Andreas Maetzel M.D., M.Sc., Ph.D., Sr. VP of Medical (Age 55)
- Mr. John B. McKune, VP of Fin. (Age 42)
- Dr. Edward P. Feener Ph.D., Chief Scientific Officer (Age 58)
Has KalVista Pharmaceuticals been receiving favorable news coverage?
Media stories about KALV stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. KalVista Pharmaceuticals earned a coverage optimism score of 0.09 on Accern's scale. They also gave news articles about the specialty pharmaceutical company an impact score of 45.89 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of KalVista Pharmaceuticals?
Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is KalVista Pharmaceuticals' stock price today?
One share of KALV stock can currently be purchased for approximately $9.22.
How big of a company is KalVista Pharmaceuticals?
KalVista Pharmaceuticals has a market capitalization of $102.89 million and generates $1.50 million in revenue each year. KalVista Pharmaceuticals employs 28 workers across the globe.
How can I contact KalVista Pharmaceuticals?
KalVista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]
MarketBeat Community Rating for KalVista Pharmaceuticals (KALV)
MarketBeat's community ratings are surveys of what our community members think about KalVista Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALV will underperform the S&P 500 over the long term. You may vote once every thirty days.
KalVista Pharmaceuticals (NASDAQ:KALV) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for KalVista Pharmaceuticals in the last 12 months. Their average twelve-month price target is $27.00, suggesting that the stock has a possible upside of 192.84%. The high price target for KALV is $27.00 and the low price target for KALV is $27.00. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $27.00 | $27.00 | $27.00 | $27.00 |
| Price Target Upside: | 192.84% upside | 177.21% upside | 177.21% upside | 177.21% upside |
KalVista Pharmaceuticals (NASDAQ:KALV) Consensus Price Target History
KalVista Pharmaceuticals (NASDAQ:KALV) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/16/2017 | BTIG Research | Boost Price Target | Buy | $18.00 -> $27.00 | N/A |  |
(Data available from 4/20/2016 forward)
KalVista Pharmaceuticals (NASDAQ:KALV) Earnings History and Estimates Chart
KalVista Pharmaceuticals (NASDAQ KALV) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 3/16/2018 | Q3 2018 | | ($0.49) | | $2.33 million | View | N/A | |
| 12/14/2017 | Q2 2018 | ($0.45) | ($0.50) | | $1.13 million | View | N/A | |
| 9/14/2017 | Q1 2018 | ($0.59) | ($0.51) | | $0.10 million | View | N/A | |
| 7/27/2017 | Q4 2017 | | ($0.43) | | $0.11 million | View | N/A | |
| 11/8/2016 | Q3 2016 | ($0.21) | ($0.09) | | $0.01 million | View | N/A | |
| 8/12/2016 | Q1 2017 | ($3.50) | ($3.92) | | $0.01 million | View | N/A | |
| 5/12/2016 | Q4 2016 | ($2.66) | ($3.50) | | $0.01 million | View | N/A | |
| 3/30/2016 | Q3 2016 | | ($2.66) | | $0.01 million | View | N/A | |
| 11/11/2015 | Q315 | ($0.26) | ($0.19) | $0.01 million | $0.01 million | View | Listen | |
| 8/11/2015 | Q215 | ($0.21) | ($0.37) | $0.01 million | $0.01 million | View | Listen | |
| 5/19/2015 | Q4 2015 | ($2.38) | ($103.36) | | $0.01 million | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
KalVista Pharmaceuticals (NASDAQ:KALV) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
KalVista Pharmaceuticals (NASDAQ KALV) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 49.10%
Institutional Ownership Percentage: 60.09%
KalVista Pharmaceuticals (NASDAQ KALV) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/12/2017 | Holdings A/S Novo | Major Shareholder | Sell | 2,725,283 | $9.64 | $26,271,728.12 | | |
| 10/12/2017 | Rajeev M Shah | Director | Buy | 850,000 | $8.50 | $7,225,000.00 | | |
| 9/15/2017 | Holdings A/S Novo | Major Shareholder | Sell | 176,647 | $7.21 | $1,273,624.87 | 2,876,027 | |
| 9/14/2017 | Holdings A/S Novo | Major Shareholder | Sell | 10,000 | $8.05 | $80,500.00 | 2,876,027 | |
| 9/13/2017 | Holdings A/S Novo | Major Shareholder | Sell | 25,900 | $8.02 | $207,718.00 | 2,876,027 | |
| 12/30/2015 | David Renzi | CEO | Sell | 10,000 | $3.70 | $37,000.00 | | |
| 4/14/2015 | Acmp Iv Llc | Major Shareholder | Buy | 877,500 | $5.00 | $4,387,500.00 | | |
| 4/14/2015 | Albert Cha | Director | Buy | 1,012,500 | $5.00 | $5,062,500.00 | | |
(Data available from 1/1/2013 forward)
KalVista Pharmaceuticals (NASDAQ KALV) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Management Report
finance.yahoo.com - April 3 at 10:16 AM |
 | KalVista Pharmaceuticals Reports Fiscal Third Quarter Results ... - Business Wire (press release)
www.businesswire.com - March 16 at 4:13 PM |
 | Critical Review: ChemoCentryx (CCXI) versus Kalvista Pharmaceuticals (KALV)
www.americanbankingnews.com - March 15 at 5:18 PM |
| Kalvista Pharmaceuticals (KALV) & Sonoma Pharmaceuticals (SNOA) Head-To-Head Analysis
www.americanbankingnews.com - March 13 at 10:22 AM |
| KalVista Pharmaceuticals to Present at 30th Annual ROTH Conference
finance.yahoo.com - March 5 at 10:59 AM |
| Head-To-Head Contrast: Kalvista Pharmaceuticals (KALV) vs. Catalyst Biosciences (CBIO)
www.americanbankingnews.com - March 4 at 7:08 PM |
| KalVista Pharmaceuticals (KALV) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - February 5 at 12:58 AM |
| Reviewing Kadmon (KDMN) & KalVista Pharmaceuticals (KALV)
www.americanbankingnews.com - January 25 at 9:48 AM |
 | Merck Has Strong Conviction In KalVista's Phase 2 Clinical Trial Of KVD001 In DME - Seeking Alpha
seekingalpha.com - January 24 at 3:23 PM |
| Contrasting KalVista Pharmaceuticals (KALV) and Argos Therapeutics (ARGS)
www.americanbankingnews.com - January 24 at 11:20 AM |
 | BRIEF-Kalvista Pharmaceuticals Commences Two Clinical Trials
www.reuters.com - January 5 at 10:55 AM |
| Contrasting KalVista Pharmaceuticals (KALV) and The Competition
www.americanbankingnews.com - January 3 at 7:06 PM |
| KalVista Pharmaceuticals (KALV) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - January 1 at 7:28 PM |
| ETFs with exposure to KalVista Pharmaceuticals, Inc. : January 1, 2018
finance.yahoo.com - January 1 at 4:12 PM |
| Analyzing KalVista Pharmaceuticals (KALV) & Its Rivals
www.americanbankingnews.com - December 31 at 5:30 AM |
| Reviewing KalVista Pharmaceuticals (KALV) and The Competition
www.americanbankingnews.com - December 28 at 12:16 AM |
| ETFs with exposure to KalVista Pharmaceuticals, Inc. : December 19, 2017
finance.yahoo.com - December 19 at 4:14 PM |
| KalVista Pharmaceuticals, Inc. :KALV-US: Earnings Analysis: Q2, 2018 By the Numbers : December 18, 2017
finance.yahoo.com - December 18 at 4:12 PM |
| KalVista Pharmaceuticals Reports Fiscal Second Quarter Results - Business Wire (press release)
www.businesswire.com - December 16 at 10:42 AM |
| KalVista Pharmaceuticals (KALV) Releases Earnings Results, Misses Expectations By $0.05 EPS
www.americanbankingnews.com - December 15 at 4:08 PM |
| KalVista Pharmaceuticals (KALV) & Its Peers Financial Survey
www.americanbankingnews.com - December 11 at 11:22 PM |
| Head to Head Survey: KalVista Pharmaceuticals (KALV) vs. Its Peers
www.americanbankingnews.com - December 8 at 7:46 PM |
| KalVista Pharmaceuticals to Present at Stifel Healthcare Conference - Business Wire (press release)
www.businesswire.com - November 8 at 11:19 AM |
| KalVista Pharmaceuticals to Present at Stifel Healthcare Conference
finance.yahoo.com - November 8 at 11:19 AM |
| KalVista Pharmaceuticals (KALV) vs. Sinovac Biotech (SVA) Head-To-Head Review
www.americanbankingnews.com - October 30 at 9:22 PM |
| BRIEF-Longwood Fund II reports 8.7 pct stake in Kalvista Pharmaceuticals
www.reuters.com - October 21 at 7:09 PM |
| KalVista Pharmaceuticals Inc (KALV): Time For A Financial Health Check
finance.yahoo.com - October 21 at 7:09 PM |
| KalVista, Notable Investment and Collaboration Agreement
finance.yahoo.com - October 18 at 5:57 AM |
| Insider Buying: KalVista Pharmaceuticals, Inc. (KALV) Director Buys 850,000 Shares of Stock
www.americanbankingnews.com - October 16 at 7:22 PM |
| KalVista Pharmaceuticals, Inc. (KALV) Given New $27.00 Price Target at BTIG Research
www.americanbankingnews.com - October 16 at 10:08 AM |
| Holdings A/S Novo Sells 2,725,283 Shares of KalVista Pharmaceuticals, Inc. (KALV) Stock
www.americanbankingnews.com - October 12 at 10:20 PM |
 | Merck Acquires 9.9% Stake In KalVista
www.rttnews.com - October 12 at 3:02 AM |
| Today's Research Reports on Stocks to Watch: KalVista Pharmaceuticals and Nutanix Inc.
finance.yahoo.com - October 11 at 5:00 PM |
| Company News For Oct 11, 2017
finance.yahoo.com - October 11 at 5:00 PM |
| ETFs with exposure to KalVista Pharmaceuticals, Inc. : October 11, 2017
finance.yahoo.com - October 11 at 5:00 PM |
 | KalVista Pharmaceuticals (KALV) Reports Collaboration with Merck (MRK) on Continuing Development of KVD001
www.streetinsider.com - October 11 at 5:40 AM |
 | KalVista Pharmaceuticals Inc. (KALV) Is Surging On Merck Collaboration
www.nasdaq.com - October 11 at 5:40 AM |
| BRIEF-Kalvista Pharmaceuticals announces collaboration with Merck
www.reuters.com - October 11 at 5:40 AM |
| Analyzing KalVista Pharmaceuticals (KALV) and Peregrine Pharmaceuticals (PPHM)
www.americanbankingnews.com - October 10 at 10:20 PM |
| KalVista Pharmaceuticals Announces Collaboration with Merck
finance.yahoo.com - October 10 at 7:35 PM |
| UPDATE: KalVista shares surge 111% on news of Merck ownership stake, collaboration
finance.yahoo.com - October 10 at 7:35 PM |
| KalVista Pharma Wins Big on Merck Collaboration
finance.yahoo.com - October 10 at 7:35 PM |
| KalVista Shares Skyrocket On Merck Collaboration, Ovid Pops -- Biotech Movers
finance.yahoo.com - October 10 at 7:35 PM |
| Merck takes stake in small Cambridge rare disease biotech, lifting shares
finance.yahoo.com - October 10 at 7:34 PM |
| Small-Cap Biotech Rockets After Dow's Merck Buys 10% Stake
finance.yahoo.com - October 10 at 7:34 PM |
| Should You Buy KalVista Pharmaceuticals Inc (KALV) For This Reason?
finance.yahoo.com - October 5 at 5:59 AM |
| Financial Analysis: Kadmon Holdings (KDMN) versus KalVista Pharmaceuticals (KALV)
www.americanbankingnews.com - September 28 at 10:20 AM |
| ETFs with exposure to KalVista Pharmaceuticals, Inc. : September 19, 2017
finance.yahoo.com - September 19 at 9:59 PM |
| KalVista Pharmaceuticals (KALV) and Cardiome Pharma Corporation (CRME) Financial Survey
www.americanbankingnews.com - September 18 at 10:30 PM |
| KalVista Pharmaceuticals, Inc. :KALV-US: Earnings Analysis: Q1, 2018 By the Numbers : September 18, 2017
finance.yahoo.com - September 18 at 7:43 PM |
KalVista Pharmaceuticals (NASDAQ:KALV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
KalVista Pharmaceuticals (NASDAQ:KALV) Income Statement, Balance Sheet and Cash Flow Statement
KalVista Pharmaceuticals (NASDAQ KALV) Stock Chart for Friday, April, 20, 2018
Loading chart…
